Entellus Medical

Entellus Medical is focused on providing unique solutions to the unmet needs of the ENT (ear, nose and throat) physician, their patients, and payers through the development of innovative device technology and treatment solutions. The Company provides a simple, direct and effective treatment for Chronic Rhinosinusitis (CRS) that is less invasive, reduces pain and bleeding, shortens recovery time, and eliminates the need for general anesthesia. Entellus recently introduced FinESS Sinus Treatment, a simple and direct approach to effectively treat patients with CRS. FinESS can be performed under local anesthesia, with or without light sedation, and remodels the maxillary ostium and the ethmoid infundibulum using a microendoscope and a small balloon catheter. Unlike sinus surgery techniques, FinESS does not require the removal of delicate bone or sinus tissue, resulting in shorter treatment time with very little pain or bleeding. Recovery time is usually one to two days with many patients resuming normal activity within a day.

Company Growth (employees)
Plymouth, US
Size (employees)
280 (est)
Entellus Medical was founded in 2006 and is headquartered in Plymouth, US

Key People/Management at Entellus Medical

Brian Farley

Brian Farley

President, CEO & Board Chairman
Margaret Boiano

Margaret Boiano

VP, Healthcare Policy & Reimbursement
Stephen Paidosh

Stephen Paidosh

VP, Operations

Entellus Medical Office Locations

Entellus Medical has an office in Plymouth
Plymouth, US (HQ)
3600 Holly Lane North
Show all (1)

Entellus Medical Financials and Metrics

Entellus Medical Financials

Entellus Medical's revenue was reported to be $75.2 m in FY, 2016

Revenue (Q2, 2017)

22.1 m

Gross profit (Q2, 2017)

16.3 m

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(8 m)

EBIT (Q2, 2017)

(7.6 m)

Market capitalization (23-Feb-2018)

598.7 m

Cash (30-Jun-2017)

62.9 m


544.9 m
Entellus Medical's current market capitalization is $598.7 m.
USDFY, 2015FY, 2016


61.6 m75.2 m

Revenue growth, %


Cost of goods sold

14.1 m18.7 m

Gross profit

47.5 m56.5 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


15.2 m14.8 m16.9 m18.7 m17.9 m19.1 m22.1 m

Cost of goods sold

3.3 m3.4 m4 m4.5 m4.6 m4.9 m5.8 m

Gross profit

11.8 m11.4 m12.9 m14.3 m13.2 m14.2 m16.3 m

Gross profit Margin, %

USDFY, 2015FY, 2016


28.5 m21.4 m

Accounts Receivable

10.4 m


3.9 m7.2 m

Current Assets

83 m54.9 m
USDQ2, 2015Q3, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2017


7.5 m8.7 m8 m15.2 m65.2 m62.9 m

Accounts Receivable

9.3 m10.2 m


2.4 m3.3 m4.7 m5.9 m7.3 m7.7 m

Current Assets

92.8 m89.1 m64.6 m58.3 m91.2 m88.7 m
USDFY, 2015FY, 2016

Net Income

(18.3 m)(28.7 m)

Depreciation and Amortization

1 m2.1 m


(1.5 m)(3.3 m)

Accounts Payable

(206 k)596 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9 m)(6.1 m)(6.9 m)(5 m)(9.5 m)(8.3 m)

Accounts Receivable

8.4 m9.3 m10.2 m


2.6 m2.4 m3.3 m4.7 m5.9 m7.3 m

Accounts Payable

2 m2.3 m3.4 m3.1 m4 m2.6 m
Y, 2017


-71.3 x

Financial Leverage

1.5 x
Show all financial metrics

Entellus Medical Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
SpiroxJuly 07, 2017$81 m

Entellus Medical Market Value History

Entellus Medical's Web-traffic and Trends

Entellus Medical Company Life and Culture

You may also be interested in